Magnetic Resonance Angiography and Doppler Scanning for Detecting Atherosclerotic Renal Artery Stenosis  by Ng, Yee-Yung et al.
J Chin Med Assoc • June 2010 • Vol 73 • No 6300
© 2010 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
Introduction
Atherosclerotic renal artery stenosis (ARAS) is one of
the most common primary diseases of the renal arteries.1
It can occur alone (isolated anatomical RAS) or in asso-
ciation with hypertension, renal insufficiency (ischemic
nephropathy), or both.2 Echo-color Doppler has
emerged as a reliable method for the diagnostic work-up
of patients with suspected renovascular stenosis. The
prevalence of ARAS ranged from 2.32% in 5,950 hyper-
tensive patients3 to 6.8% in the elderly population,4 as
determined by renal Doppler scanning (RDS). This
prevalence determined by RDS3,4 was much lower
than that reported using cardiac catheterization or
aortography (11–42%)5–7 and autopsy (4–53%).8–11
This implies that ARAS in many patients is not de-
tected by RDS,12–14 although the sensitivity and specifi-
city of RDS for ARAS has been reported to range
from 63% to 100% and 73% to 100%, respectively.15,16
These sensitivities and specificities of RDS in patients
with ARAS were mainly found in western countries,
and not in large groups in Taiwan.
ARAS is a progressive17,18 but potentially revers-
ible chronic kidney disease.18–20 The damage to renal
function, and its related morbidity and mortality, can
be avoided if ARAS is diagnosed and treated early.20,21
Therefore, it is essential to detect ARAS and initiate
medical or interventional therapy early to maintain the
renal blood flow above the critical perfusion pressure,
to prevent renal ischemic damage.
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This study used magnetic resonance angiography
(MRA) to evaluate the sensitivity and specificity of RDS
for detecting ARAS among aged patients at a ne-
phrology clinic, and the degree of underestimation of
ARAS by RDS.
Methods
Patients
ARAS is a disease of aging. Therefore, we enrolled 257
unselected patients, aged ≥ 50 years, who were visiting
the outpatient nephrology clinic of Taipei Veterans
General Hospital. Written informed consent was ob-
tained from all patients. This study followed the
Declaration of Helsinki, and was approved by the Ins-
titutional Research Board. Each patient underwent
MRA after RDS and effective renal perfusion tests.
Renal angiography is the undisputed gold standard in
the diagnostic work-up for renovascular disease; there-
fore, confirmation by selective renal angiography was
encouraged for patients with > 50% renal artery steno-
sis, as shown by MRA. The diagnosis and severity of
ARAS was defined by MRA if selective renal angiog-
raphy was not performed. Four grades were used to
categorize the severity of ARAS: grade 1, < 25% steno-
sis; grade 2, 26–50%; grade 3, 51–75%; and grade 4,
> 75%. Stenosis of > 50% was defined as significant.
Demographic data were collected, including age,
sex, body weight and height, and history of smoking
and alcohol consumption. Comorbid conditions, in-
cluding underlying coronary artery disease (CAD),
cerebrovascular disease, and diabetes mellitus were
also recorded.
Laboratory tests
Blood pressure was measured before RDS. Creatinine
clearance (Ccr) and urinary protein excretion were
determined after 24-hour urine collection. Serum
blood urea nitrogen, creatinine (Scr), cholesterol, uric
acid, calcium, phosphate and albumin concentrations
were measured by standard laboratory methods. Plasma
renin activity, aldosterone and intact parathyroid hor-
mone were measured using radioimmunoassay.
RDS
All RDS was performed by a registered technologist,
and the diagnosis was made by a radiologist with
extensive experience in ultrasonography. The 257
patients were scanned in the supine position using a
multifrequency curved-array transducer (2–5 MHz).
Doppler samples were taken from each renal artery
and interlobar artery by a bilateral flank approach,
while maintaining the angle of insonation at < 60°. The
angle of insonation was estimated and combined with
the spectral analysis from the Doppler-shifted signal,
and the renal artery peak systolic velocity was esti-
mated. In the decubitus position, a B-scan image of
each kidney was obtained and kidney length deter-
mined. The result of the RDS examination was con-
sidered positive for RAS according to the following
published criteria: (1) presence of turbulence before
and after stenosis, with a color change (confetti phe-
nomenon); (2) maximum flow velocity > 180 cm/sec
at stenosis, with concomitant spectral broadening and
aliasing (no Doppler signal was obtained from an
imaged artery in the case of renal artery occlusion);
(3) end-diastolic velocity >50cm/sec; (4) post-stenotic
drop in velocity; (5) acceleration time > 0.07 seconds
and slope of systolic upstroke < 3 m/s2; or (6) resis-
tance index associated with stenosis or occlusion of
the segmental arteries < 0.5.
MRA
MRA was performed with parallel technique (asset
number 1.50) using the following parameters: mini-
mum echo time 0.9–1 millisecond; flip angle = 30°;
bandwidth = 62.5 kHz; matrix size = 320 × 192; field
of view = 35–40 cm; number of excitations = 1; slice
thickness = 3.2 mm with zero interpolation; and loca-
tions per slab = 36. A standard bolus of 0.1 mmol/kg
gadolinium–diethylenetriamine pentaacetic acid was in-
jected into an antecubital vein at a flow rate of 4 mL/
sec. The degree of stenosis was determined by review-
ing and measuring both coronal raw data and the
coronal maximum-intensity projection, expressed as
180° rotational view (5°/frame), and was calculated
as the diameter of the stenotic segment divided by the
diameter of post-stenotic normal segment. Locations
and lengths of stenosis were also measured.
Renal artery angioplasty and renal artery stent
Despite the risks of contrast nephropathy and athero-
embolic renal disease, arteriography is considered to
be the gold-standard diagnostic test. Twenty-four
hours before and after angiography, patients were
given hydration,22 0.6 g N-acetylcystine23 and sodium
bicarbonate24 to prevent iodinated contrast-induced
nephropathy. A femoral artery approach was used
after reviewing the MRA in each case. Aortography
was performed first to check the general condition of
the abdominal aorta and the renal arteries. Renal
arteriograms were then taken for both kidneys and all
the renal arteries. A Cobra or RLG catheter was used
with a marker wire inside. The diameter and the
stenotic segment of the renal artery were measured as
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compared with the marker wire. If the stenosis was
> 50%, percutaneous transluminal angioplasty with a
stent was carried out at the same time using a pre-
mount balloon-expandable stent. The size of the stent
was chosen to be the same as or 10% larger than the
normal renal arterial diameter. After introducing an
angiosheath, a 6- or 7-Fr guiding catheter was ad-
vanced near the renal arterial orifice. The stent was
advanced to cross the stricture segment. The position
of the stent was checked by injection of contrast med-
ium through the guiding catheter. The stent was then
deployed after inflating the pressure gauge. Finally,
renal arteriography was performed again, either by
the guiding or diagnostic catheter, to check for dis-
section, bleeding or thrombosis.
Statistical analysis
Statistical analysis was conducted by the χ2 test, Stu-
dent’s t test, Mann–Whitney test and logistic regression
using SPSS Version 15.0 (SPSS Inc., Chicago, IL, USA).
The variance inflation factor (VIF) was used to measure
colinearity among independent variables in multiple
regression analysis. The larger the value of VIF, the more
troublesome was the variable. Generally, VIF >10 indi-
cates colinearity among predictor variables. VIF values
are easily produced using SPSS (SPSS Inc.). A p value
< 0.05 indicated statistical significance.
Results
The mean age and Scr levels of the 257 patients (192
male and 65 female) were 75.49 ± 8.63 years and
2.39 ± 1.42 mg/dL (range, 0.6–1.5 mg/dL), respec-
tively. Thirty-seven (14.4%) and 139 (54.1%) patients
were diagnosed with ARAS by RDS and MRA, respec-
tively. Among the 37 patients diagnosed by RDS, 14
stenoses occurred on the right side, 14 on the left,
and 9 were bilateral. Among the 139 patients with
stenosis diagnosed by MRA, 44 stenoses were found
on the right side, 38 on the left, and 57 were bilateral.
Ninety-five of 139 (68.3%) patients who were diag-
nosed with ARAS by MRA were willing to undergo
selective renal angiography for confirmation. Twenty-
eight of 37 (75.7%) patients whose stenoses were diag-
nosed by RDS were also shown to have ARAS by MRA.
The diagnosis of stenosis made by MRA in 87 of 95
(91.6%) patients was confirmed by selective renal an-
giography. After eliminating the 8 patients who had
negative results by selective renal angiography, there
were 186 renal arteries with ARAS in the 131 patients
who had true-positive results. This study showed a
sensitivity of 20.14%, specificity of 92.37%, and positive
Table 1. Results of atherosclerotic renal artery stenosis categorized
by renal Doppler scanning and magnetic resonance angiography
ARAS proved by MRA
Stenosis Normal
ARAS diagnosed by RDS
Stenosis 28 9
Normal 111 109
Total 139 118
Sensitivity 20.14% (28/139)
Specificity 92.37% (109/118)
PPV 75.68% (28/37)
NPV 49.55% (109/220)
Accuracy 53.31% (137/257)
ARAS = atherosclerotic renal artery stenosis; RDS = renal Doppler scanning;
MRA = magnetic resonance angiography; PPV = positive predictive value;
NPV = negative predictive value.
predictive value of 75.68%, with an overall accuracy of
53.32% (Table 1). Seventy-nine of 186 (42.5%) renal
arteries were considered to have significant (> 50%)
stenosis (Table 2).
Compared with the 126 patients without ARAS,
the group of 131 patients with ARAS were older (mean
age, 77.17 ± 7.64 vs. 73.74 ± 9.27 years, p = 0.001) and
included a significantly higher number of smokers
(65 vs. 43, p = 0.011) (Table 3). The smokers in the
group with ARAS also smoked more (0.49 ± 0.6 vs.
0.29 ± 0.52 packs per day, p = 0.005) and had smoked
longer (21.93 ± 23.99 vs. 12.24 ± 20.10 years, p =
0.001) than those in the group without ARAS. The
number of patients with CAD in the group with ARAS
was significantly higher than in the group without
ARAS (37 vs. 12, p <0.001), as was the Scr level [mean,
2.54 ± 1.53 mg/dL (median, interquartile range, 2,
1.4) vs. 2.24 ± 1.28 mg/dL (1.85, 1.4), p = 0.083]
and the number of patients with Scr level > 4 mg/dL
(23 vs. 9). The Ccr rate (27.55 ± 12.61 vs. 32.83 ±
17.32 mL/min, p = 0.006) and the effective renal
plasma flow (ERPF) (165.56±64.39 vs. 189.85±92.7
mL/min, p = 0.023) were significantly lower in the
group with ARAS than in that without (Table 3).
Among the 220 patients with negative results from
RDS, there were 111 (50.45%) whose ARAS was di-
agnosed by MRA (Table 4). Compared with the
patients with negative MRA results, this group of 
111 patients with positive MRA results were older
(77.82 ± 6.51 vs. 73.84 ± 9.56 years, p = 0.001), had
more smokers (57 vs. 35, p = 0.002) who smoked more
(0.5 ± 0.59 vs. 0.26 ± 0.51 packs per day, p = 0.001)
and who had done so for longer (22.8 ± 24.16 vs.
11.21 ± 20.08 years, p = 0.001). The number of pa-
tients with CAD (30 vs. 11, p = 0.001), the average 
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Scr levels [mean, 2.66±1.63mg/dL (median, interquar-
tile range, 2.1, 1.6) vs. 2.19 ± 1.06 mg/dL (1.9, 1.4),
p = 0.04], and the number of patients with Scr levels
>4mg/dL (23 vs. 6, p=0.001) were significantly higher
in the group with results that were negative by RDS
but positive by MRA, than the group whose results
were negative by both methods. In contrast, Ccr (26.2±
11.73 vs. 32.5 ± 16.54 mL/min, p = 0.001) and ERPF
(160±63.59 vs. 185.8±86.49mL/min, p=0.018) were
significantly lower in the group whose results were
negative by RDS but positive by MRA than in the
group whose results were negative by both methods
(Table 4). The number of patients with > 75% RAS in
the positive RDS group was significantly higher than
in the negative RDS group [14/28 (50%) vs. 28/111
(25.23%), p = 0.02]. In a multivariate logistic regres-
sion analysis (Table 5), sex, age > 65 years, smoking
duration, CAD, Scr > 4 mg/dL, Ccr and ERPF were
included in the final model as significant and indepen-
dent factors. The variables in this model were [odds
ratio (95% confidence interval)]: sex, 1.306 (0.552–
3.09), p = 0.543; age > 65 years, 5.85 (1.757–19.48),
p = 0.004; smoking duration > 20 years, 3.095 (1.468–
6.526), p = 0.003; CAD, 1.521 (1.042–2.22), p = 0.03;
Scr level > 4 mg/dL, 5.385 (1.518–19.102), p = 0.009;
Ccr, 1.001 (0.96–1.044), p = 0.96; and ERPF, 0.998
(0.99–1.005), p = 0.524.
Discussion
Although the most accurate anatomical tests include
RDS, MRA and computed tomographic angiography,25
the latter was not used for this study because of 
the risk of ionizing radiation and a high incidence of
contrast-induced nephropathy,26 especially for patients
with preexisting renal failure.27 The mean Scr level of
2.39 ± 1.42 mg/dL (normal range, 0.6–1.5 mg/dL)
in our patients further supported the decision against
using computed tomographic angiography for further
evaluation of ARAS after RDS used at the beginning
of this study. In contrast, the use of intravenous
gadolinium-based contrast media in magnetic reso-
nance imaging has been found not to cause ne-
phropathy in patients with renal insufficiency.28,29
Although nephrogenic systemic fibrosis related to non-
nephrotoxic gadolinium-based contrast media has been
reported in some patients with renal failure, factors such
as dose of gadolinium and predisposing infection seem
to play a role.29–32 There were no cases of nephro-
genic systemic fibrosis in this or our previous study.29
For the present study, the number of true-negative
results was defined as the total number of patients
Table 2. Demographic and clinical characteristics of 257 patients
who underwent Doppler scanning and magnetic resonance
angiography*
Characteristic Value
Male 192 (74.4)
Age (yr) 75.49 ± 8.63
Patients with stenosis 131 (51.0)
No. of stenotic arteries 186/514 (36.2)
Grade 1 (right/left) 43 (21/22)
Grade 2 (right/left) 64 (36/28)
Grade 3 (right/left) 35 (14/21)
Grade 4 (right/left) 44 (26/18)
Body weight (kg) 65.29 ± 11.27
Height (cm) 162.32 ± 8.21
Smoking 108 (42.0)
Packs per day 0.39 ± 0.57
Duration (yr) 17.18 ± 22.65
Alcohol consumption 41 (16.0)
Amount (glasses) 0.32 ± 0.92
Duration (yr) 6.16 ± 15.54
Diabetes mellitus 91 (35.4)
Duration (yr) 14.49 ± 9.36
Hypertension 219 (85.2)
Duration (yr) 17.15 ± 12.38
Systolic BP (mmHg) 138.53 ± 18.51
Diastolic BP (mmHg) 74.51 ± 11.38
Previous CAD 49 (19.1)
1 vessel 11 (22.5)
2 vessels 17 (34.7)
3 vessels 21 (42.9)
Previous CVA 29 (11.3)
Renin (3–33 pg/mL) 36.26 ± 45.39
Aldosterone (40–310 pg/mL) 173.09 ± 141.53
Intact PTH (< 50 pg/mL) 96.03 ± 86.56
Albumin (3.7–5.3 g/dL) 3.99 ± 0.47
Calcium (8.4–10.6 mg/dL) 9.09 ± 0.66
Cholesterol (125–240 mg/dL) 167.27 ± 36.05
BUN (19.6–56.0 mmol/L) 90.79 ± 50.87
Uric acid (2.5–7.2 mg/dL) 7.07 ± 1.98
Creatinine (0.6–1.5 mg/dL) 2.39 ± 1.42
Creatinine > 4 mg/dL 32 (12.5)
Potassium (3.4–4.7 mmol/L) 4.28 ± 0.59
Phosphate (2.1–4.7 mg/dL) 3.67 ± 0.90
BMI (kg/m2) 24.76 ± 3.78
Ccr (mL/min) 30.15 ± 15.31
*Continuous variables are expressed as mean ± standard deviation and cat-
egorical data as n (%).The normal ranges of laboratory tests are in parentheses.
BP = blood pressure; CAD = coronary artery disease; CVA = cerebrovascular
accident; PTH = parathyroid hormone; BUN = blood urea nitrogen; BMI = body
mass index; Ccr = creatinine clearance.
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Table 3. Demographic and clinical characteristics of 257 patients with and without atherosclerotic renal artery stenosis*
Characteristic With stenosis (n = 131) Without stenosis (n = 126) p
Male 104 (79.4) 88 (68.9) 0.086
Age (yr) 77.17 ± 7.64 73.74 ± 9.27 0.001
Body weight (kg) 64.72 ± 10.77 65.86 ± 11.78 0.418
Height (cm) 162.23 ± 7.87 162.41 ± 8.57 0.854
Smoking 65 (51.6) 43 (35.5) 0.015
Packs per day, median (IQR) 0.195 (0–1) 0 (0–0.5) 0.003
Duration (yr), median (IQR) 13.5 (0–50) 0 (0–25) 0.002
Alcohol consumption 18 (14.2) 23 (19.0) 0.312
Amount (glasses) 0.33 ± 1.01 0.31 ± 0.82 0.690
Duration (yr) 5.79 ± 16.02 6.55 ± 15.07 0.940
Diabetes mellitus 45 (34.6) 46 (38.0) 0.601
Duration (yr) 13.70 ± 9.64 15.29 ± 9.11 0.412
Hypertension 112 (86.2) 107 (87.0) 0.856
Duration (yr) 16.40 ± 12.40 17.92 ± 12.37 0.385
Systolic BP (mmHg) 139.62 ± 20.63 137.40 ± 16.07 0.377
Diastolic BP (mmHg) 75.18 ± 11.50 73.81 ± 11.27 0.378
Previous CAD 37 (29.6) 12 (10.0) < 0.001
Previous CVA 16 (13.0) 13 (10.9) 0.694
Renin (3–33 pg/mL), median (IQR) 21.76 (11.12–51.96) 14.64 (8.48–39.16) 0.112
Aldosterone (40–310 pg/mL) 164.83 ± 144.67 189.00 ± 135.13 0.296
iPTH (< 50 pg/mL), median (IQR) 64.74 (39.02–97.64) 84.5 (56.02–121.0) 0.091
Albumin (3.7–5.3 g/dL) 3.97 ± 0.47 4.02 ± 0.49 0.748
Calcium (8.4–10.6 mg/dL) 9.03 ± 0.58 9.16 ± 0.76 0.252
Cholesterol (125–240 mg/dL) 165.24 ± 34.14 170.37 ± 38.84 0.454
BUN (19.6–56.0 mmol/L) 103.28 ± 55.66 92.07 ± 44.85 0.08
Uric acid (2.5–7.2 mg/dL) 7.25 ± 1.95 6.84 ± 2.00 0.294
Cr (0.6–1.5 mg/dL), median (IQR) 2 (1.6–3.0) 1.85 (1.4–2.8) 0.083
Cr > 4 mg/dL 23 (17.6) 9 (7.1) 0.014
Potassium (3.4–4.7 mmol/L) 4.30 ± 0.62 4.26 ± 0.55 0.659
Phosphate (2.1–4.7 mg/dL) 3.65 ± 0.98 3.71 ± 0.74 0.679
BMI (kg/m2) 24.59 ± 3.7 24.93 ± 3.87 0.470
Ccr (mL/min), median (IQR) 27.56 (18.86–32.83) 29.84 (19.26–41.41) 0.031
*Continuous variables are expressed as mean ± standard deviation and categorical data as n (%). Median with IQR, and Mann–Whitney test were used for the
non-normally distributed data. IQR = interquartile range; BP = blood pressure; CAD = coronary artery disease; CVA = cerebrovascular accident; iPTH = intact
parathyroid hormone; BUN = blood urea nitrogen; Cr = creatinine; BMI = body mass index; Ccr = creatinine clearance.
minus the number of true-positive results (i.e. 257–
139 = 118). This study showed that the sensitivity,
specificity, and positive predictive value of RDS for
ARAS in outpatients were 20.14% (28/139), 92.37%
(109/118) and 75.68% (28/37), respectively (Table
1). One hundred and eleven of the 220 (50.45%) pa-
tients who had negative results by RDS had a diagnosis
of ARAS made by contrast-enhanced MRA. Specifi-
cally, stenosis was found in 154 of the 222 (69.37%)
renal arteries of these 111 patients, and significant
stenosis (> 50%) was found in 60 (38.96%) (Table 4).
The superior results obtained using MRA suggest that
MRA significantly reduces interobserver variability and
offers reliable and reproducible grading of RAS based
on stenosis morphology and hemodynamic changes.33
The high proportion (80%, 111/139) of ARAS cases
missed by RDS in the present study might be partially
related to a high technical failure rate and operator
dependence.34 Doppler flow volume measurements
require the calculation of vessel diameter, which can
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introduce considerable error. In contrast, RDS de-
mands optimal sonographic test conditions and is lim-
ited by patient obesity and intestinal gas overlying the
area of interest.35 The large variability in duplex results
among different laboratories has been attributed to
differences in the type of ultrasound machine, the trans-
ducer, and the operator. Laboratory-specific rather than
published duplex criteria have been suggested for the
assessment of carotid and renal artery stenosis.36–38
RDS also has been reported to be sufficiently sensitive
Table 4. Demographic and clinical characteristics of 220 patients with negative Doppler scanning results*
Characteristic Patients with MRA(–) (n = 109) Patients with MRA(+) (n = 111)† p
Male 78 (71.6) 88 (79.3) 0.211
Age (yr) 73.84 ± 9.56 77.82 ± 6.51 0.001
No. of stenotic arteries 0/218 154/222 (69.37)
Grade 1 (right/left) 0 25 (14/11)
Grade 2 (right/left) 0 69 (34/35)
Grade 3 (right/left) 0 24 (12/12)
Grade 4 (right/left) 0 36 (19/17)
Body weight (kg) 66.22 ± 11.46 65.19 ± 10.89 0.499
Height (cm) 162.57 ± 8.20 162.24 ± 8.36 0.772
Smoking 34 (32.1) 57 (53.5) 0.002
Packs per day, median (IQR) 0 (0–0.5) 0.33 (0–1) < 0.001
Duration (yr), median (IQR) 0 (0–16.25) 20 (0–50) 0.001
Alcohol consumption 19 (17.9) 17 (15.7) 0.717
Amount (glasses) 0.27 ± 0.75 0.34 ± 0.95 0.557
Duration (yr) 5.87 ± 14.31 7.04 ± 17.7 0.671
Diabetes mellitus 39 (37.1) 42 (38.5) 0.888
Duration (yr) 15.91 ± 9.47 13.54 ± 9.42 0.275
Hypertension 90 (84.9) 94 (85. 5) 0.910
Duration (yr) 17.75 ± 12.82 17.59 ± 12.17 0.984
Systolic BP (mmHg) 136.20 ± 16.22 140 ± 19.03 0.125
Diastolic BP (mmHg) 73.35 ± 11.84 74.6 ± 10.58 0.441
Previous CAD 11 (10.5) 30 (28.0) 0.002
Previous CVA 8 (7.8) 17 (16.0) 0.087
Renin (3–33 pg/mL), median (IQR) 17.39 (9.31–39.92) 22.17 (11.35–51.96) 0.2
Aldosterone (40–310 pg/mL) 190.00 ± 147.20 168.00 ± 115.20 0.346
iPTH (< 50 pg/mL), median (IQR) 82.29 (59.6–117.75) 76.47 (49.51–114.0) 0.451
Albumin (3.7–5.3 g/dL) 3.99 ± 0.48 3.99 ± 0.43 0.957
Calcium (8.4–10.6 mg/dL) 9.16 ± 0.75 9.06 ± 0.58 0.399
Cholesterol (125–240 mg/dL) 168.80 ± 39.65 163.00 ± 34.16 0.384
BUN (19.6–56.0 mmol/L) 91.90 ± 44.37 104.48 ± 53.56 0.06
Uric acid (2.5–7.2 mg/dL) 6.91 ± 2.09 7.16 ± 1.94 0.443
Cr (0.6–1.5 mg/dL), median (IQR) 1.9 (1.4–2.8) 2.1 (1.6–3.2) 0.04
Cr > 4 mg/dL 6 (5.5) 23 (20.7) 0.001
Potassium (3.4–4.7 mmol/L) 4.26 ± 0.55 4.27 ± 0.65 0.850
Phosphate (2.1–4.7 mg/dL) 3.75 ± 0.77 3.66 ± 0.95 0.594
BMI (kg/m2) 25.02 ± 3.79 24.78 ± 3.78 0.643
Ccr (mL/min), median (IQR) 29.75 (19.30–41.30) 27.09 (18.07–32.51) 0.011
*Continuous variables are expressed as mean ± standard deviation and categorical data as n (%); †8 of 111 MRA positive patients were proven to have no
renal artery stenosis by selective angiography. Median with IQR, and Mann–Whitney test were used for the non-normally distributed data. MRA = magnetic res-
onance angiography; IQR = interquartile range; BP = blood pressure; CAD = coronary artery disease; CVA = cerebrovascular accident; iPTH = intact parathyroid
hormone; BUN = blood urea nitrogen; Cr = creatinine; BMI = body mass index; Ccr = creatinine clearance.
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Table 5. Multivariate logistic regression analysis of factors that influence atherosclerotic renal artery stenosis in 220 patients with
negative results by Doppler scanning*
OR 95% CI p
Sex (female) 1.306 0.552–3.090 0.543
Age > 65 yr† 5.850 1.757–19.480 0.004
Smoking > 20 yr† 3.095 1.468–6.526 0.003
Coronary artery disease 1.521 1.042–2.220 0.030
Creatinine > 4 mg/dL (354.4 μmol/L)† 5.385 1.518–19.102 0.009
Creatinine clearance 1.001 0.960–1.044 0.960
Effective renal perfusion 0.998 0.990–1.005 0.524
Constant 0.107 0.040
*All the variance inflation factor values in this analysis were < 4; †cut-off values for age, smoking duration and creatinine were calculated by receiver operating
characteristic curves before logistic regression. OR = odds ratio; CI = confidence interval.
for detection of high-grade RAS.39 The severity of most
RDS-undiagnosed cases (154 of 222 renal arteries) of
ARAS was < 50% in the present study, and the num-
ber of patients with > 75% RAS in the positive RDS
group was significantly higher than in the negative
RDS group (50% vs. 25.23%, p = 0.02), which also sup-
ports the results of Zeller et al.39 Overall, the above
limitations might account for the large variability in
sensitivity and accuracy in the use of RDS for the as-
sessment of ARAS in the present and a previous study.12
This could also explain why only 138 of 5,950 (2.32%)
patients with hypertension received a diagnoses of sig-
nificant RAS using RDS in the study of Radermacher
et al.3 However, RDS is relatively inexpensive and con-
venient, has severity detection ability, and avoids the use
of contrast media. These clear advantages, combined
with the high specificity (92.37%) and reasonable pos-
itive predictive value (75.68%) demonstrated in the
present study, suggest that RDS might still be the
diagnostic procedure of choice for screening outpa-
tients for ARAS. However, the 95 subjects with > 50%
RAS by MRA, which was confirmed through renal
artery angioplasty for diagnosis and treatment, were
not randomized. Therefore, the high concordance rate
of angioplasty and MRA needs further evaluation.
Although a body mass index of <25kg/m2 has been
reported as a predisposing factor for ARAS,40 it was
not apparent in our study; this might be related to the
leaner, Asian population included in this study. In our
study, cases with CAD, increased age, impaired renal
function and a history of smoking had a significantly
higher likelihood of being diagnosed with ARAS. In a
multivariate logistic regression analysis (Table 5), age
> 65 years, smoking duration, CAD and Scr > 4 mg/
dL were significant and independent factors for ARAS
in the negative RDS but positive MRA patients. These
factors reflect risk factors for generalized vascular dis-
ease,41–45 therefore, it is appropriate to recommend
MRA for those deemed to be at high risk for vascular
disease, in circumstances when RAS is considered likely
on a clinical basis.
In conclusion, RDS might still be the diagnostic
procedure of choice for screening outpatients for
ARAS. It is inexpensive and convenient, offers severity
detection, and avoids the use of contrast media. When
RDS is negative in aged people who have smoked for
> 20 years, with CAD or Scr > 4 mg/dL, MRA is rec-
ommended for further evaluation of ARAS.
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